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Abstract
The evolution of autologous neutralizing antibodies to sequential human immunodeficiency virus type 1 (HIV-1) isolates was studied
in a population of 16 children who were perinatally infected with human immunodeficiency virus type 1. The cohort included seven children
with rapid disease progression (RP) and nine who had nonrapid disease progression (NRP). Four of the NRP after 6 months of age harbored
viruses that could be neutralized by antibodies found in autologous contemporaneous plasma (titers up to 1:640) while the majority of
longitudinally collected viruses from five NRP were resistant to neutralization with contemporaneous plasma. Because of their shorter
survival, only five of the RP had studies after 6 months of age; three of the five had neutralizing antibodies to contemporaneous virus isolates
and the highest titers were 1:20. The highest titers in RP (up to 1:160) occurred in specimens obtained prior to 6 months of age but these
were most likely of maternal origin. Most isolates that were not neutralized by contemporaneous plasma could be neutralized using
noncontemporaneous plasma obtained months to years after the virus isolates. These autologous noncontemporaneous neutralizing
antibodies persisted for years, had titers that were higher to viruses isolated at younger ages, and were generally more potent in children
with NRP than RP. Demonstration of neutralizing antibodies to viruses previously resistant to neutralization by contemporaneous plasma
suggests a continuous evolution of virus variants in vivo that are able to escape the effect of neutralizing antibodies.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human immunodeficiency virus (HIV) infection is char-
acterized by chronic viremia that, untreated, results in pro-
gressive deterioration of immune function and ultimately
disease and death in most individuals. A long incubation
period in most adults and some perinatally infected children
provides evidence of an effective immune response to this
infection early in the course of infection. The identification
of a small population of infected adults, termed long-term
nonprogressors, without immune deterioration and absent or
low levels of viremia supports the possibility of effective
immunity in some patients. Understanding the nature of this
immunity could be important in the formulation of a pro-
tective vaccine or effective immunotherapy that can en-
hance the immune response.
Studies of cellular and humoral immunity to HIV have
indicated a role for both in protection. A potent cellular
immune response in primary infection as demonstrated by
the cytotoxic T cell (CTL) response that coincides with a
decline in viral load has been demonstrated by several
investigators (Koup et al., 1994; Borrow et al., 1994). The
presence of CTL response to viral antigens has also been
correlated with delay in disease onset and long-term sur-
vival (Rinaldo et al., 1995; Greenough et al., 1997; Moss et
al., 1995; Klein et al., 1995).
A role for humoral immunity in HIV infection is sug-
gested by the presence of high levels of neutralizing anti-
bodies in adults who are long-term nonprogessors in com-
parison to individuals with a more typical course whose
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neutralizing antibody levels are generally lower (Cao et al.,
1995 Pantaleo et al., 1995 Pilgrim et al., 1997). In monkeys,
the infusion of sera with neutralizing antibody prior to
challenge with virus has provided protection from infection
(Baba et al., 2000 Mascola et al., 2000; Shibata et al., 1999).
In most individuals with HIV, viremia persists and dis-
ease occurs despite the presence of neutralizing antibodies
or a CTL response. The ability of the virus to persist despite
a humoral and cellular response has been attributed in part
to its ability to mutate constantly and generate new virus
variants that are resistant to the immune response that is
present.
The role of neutralizing antibodies in protection from
infection and in the selection of new variants that are resis-
tant to neutralization is not well understood. Studies to date
have reported that neutralizing antibodies may not develop
for several months following infection (Pellegrin et al.,
1996; Lathey et al., 1997; Moog et al., 1997). In a study
using longitudinally collected specimens from a single pa-
tient, neutralizing antibodies to virus isolates were found in
both contemporaneous sera and in serum collected from the
patient subsequent to the virus isolates (Tremblay and
Wainberg, 1990). Similarly, in two other studies that in-
cluded three individuals each, autologous contemporaneous
neutralizing antibodies were not present, but were found in
sera obtained months to years after the viruses were iso-
lated. (Arendrup et al., 1992; Bradney et al., 1999).
These studies were seminal in describing the phenome-
non of neutralization resistant viruses in adults. It is not
known, however, if the results of these studies can be
generalized because the studies included only a small num-
ber of patients and only a few samples were studied for each
patient. Many questions remain about the ontogeny of neu-
tralizing antibody production in both adults and children
and the role of these antibodies in protection and pathogen-
esis.
The focus of our study was the development and evolu-
tion of autologous neutralizing antibodies to HIV-1 infec-
tion in children with perinatal infection that were followed
from birth. The study included children with both rapid
disease progression (RP) and nonrapid progression (NRP).
Results
Autologous contemporaneous neutralization
The presence of antibodies capable of neutralizing virus
isolated from the same specimen of blood (autologous con-
temporaneous neutralization, ACN) was tested in all avail-
able specimens. For the RP, ACN antibodies were present in
10 (35%) of the 28 specimens. Titers ranged from 1:10 to
1:160 (Table 1). Six of the 7 RP had specimens collected at
birth or 2 weeks of age. Four of the 6 had ACN antibodies
present. For the RP, the highest titers occurred in plasma
obtained between birth and 6 months of age. These titers
declined over time and were presumed to be maternal in
origin. Because the survival of the RP was limited, only a
small number of specimens were available after a year of
age. The highest titer of ACN antibodies in this group was
1:20.
Twenty-one (42%) of the 49 paired contemporaneous
specimens from the group of children who were NRP had
ACN antibodies (Tables 2 and 3). The titers for the NRP
ranged from 1:10 to 1:640. Contemporaneous antibodies of
presumed maternal origin were found in 3 of the 8 children
with specimens obtained between birth and 6 months of age.
These titers ranged between 1:20 and 1:40.
After 6 months of age, the occurrence of ACN antibodies
varied. They were present in the majority of specimens from
4 of 9 NRP (Table 2). Only one of the remaining 5 NRP had
fewer than 4 specimens tested for ACN antibodies that were
obtained after 6 months of age. A total of 19 specimens
from these 5 children were obtained after 6 months of age
and only 1 (5.2%) had ACN antibodies. This single speci-
men was obtained from NRP 242. Four of the 5 NRP (NRP
255, NRP 208, NRP 262, and NRP 274) harbored viruses
after 6 months of age that were consistently resistant to
neutralization using contemporaneous plasma. Titers after 6
months of age in NRP with contemporaneous antibodies
ranged between 1:10 and 1:640 (median titer 1:20).
Autologous noncontemporaneous neutralizing antibodies
To determine if neutralizing antibodies to viruses that
were predominantly resistant to neutralization with contem-
poraneous plasma developed later, virus isolates from 5
NRP children with sequential viruses obtained after 6
months of age were tested in neutralization assays. Plasma
collected subsequent to isolation of the viruses were tested
for the presence of antibodies that could neutralize the
earlier viruses (Table 3). Using plasma obtained months to
years after the isolation of the virus, all children had neu-
tralizing antibodies to the majority of viruses that had been
previously resistant to neutralization with contemporaneous
plasma. The demonstration that antibodies in a given
plasma can neutralize a previous isolate but not the contem-
poraneous provides evidence that these isolates are not the
same and have evolved in vivo in the presence of neutral-
izing antibodies. Of the 18 isolates that were resistant to
contemporaneous plasma and for which later plasma sam-
ples were available, only 4 (22.2%) could not be neutral-
ized.
Several characteristics of autologous noncontemporane-
ous neutralizing antibodies were noted in this study. Virus
isolates resistant to ACN antibodies were neutralized with
plasma collected as early as 4 to 5 months later (see NRP
262 and RP 422, Table 3). Neutralizing antibody titers to
viruses isolated from children at the earliest ages tended to
be higher than titers to viruses isolated from children when
they were older. That is, over time, the ability to make
noncontemporaneous antibody particularly to new virus iso-
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Table 1
Neutralization of sequential virus isolates from rapid progressors with antibodies in plasma collected at the same time and with plasma collected latera
Virus isolate Neutralizing antibody titer with plasma obtained at age
Birth 2 mo 6 mo 11 mo
RP 422
Birth 1:10 1:10 1:20 1:40
2 mo 1:10 1:40 1:10
6 mo 1:10
11 mo 1:10
CDC Class. N B3 C3 C3
Antiretrovirals none none ZDV ZDV
RNA copies/ml 244,972 750,000 750,000 750,000
Virus isolate Neutralizing antibody titer with plasma obtained at age
Birth 2 mo 12 mo
RP 601
Birth 1:20 1:10 1:10
2 mo 1:10 1:10
12 mo 1:10
CDC Class. N N2 C3
Antiretrovirals none none ZDV, 3TC
RNA copies/ml 319,325 750,000 750,000
Virus isolate Neutralizing antibody titer with plasma obtained at age
2 weeks 12 mo
RP 275
2 weeks 1:20 1:10
12 mo 1:10
CDC Class. N1 C1
Antiretrovirals none ZDV
RNA copies/ml 750,000 750,000
Virus isolate Neutralizing antibody titer with plasma obtained at age
2 wk 2 mo 6 mo
RP 290
2 wk 1:160 1:160 1:10
2 mo 1:40 1:10
6 mo 1:10
CDC Class. N1 C2 C3
Antiretrovirals none none none
RNA copies/ml 750,000 750,000 ND
Virus isolate Neutralizing antibody titer with plasma obtained at age
2 mo 6 mo
RP 249
2 mo 1:10 1:10
6 mo 1:10
CDC Class. N3 B3
Antiretrovirals none ZDV
RNA copies/ml ND ND
Virus isolate Neutralizing antibody titer with plasma obtained at age
2 wk 2 mo 6 mo 12 mo 24 mo 38 mo 45 mo 49 mo
RP 217
2 wk 1:10 1:10 1:10 1:10 1:20 1:40 1:40
2 mo 1:10 1:10 1:10 1:10 1:20
6 mo 1:10 1:160 1:40 1:20 1:40
12 mo 1:10 1:40 1:40 1:20
24 mo 1:20 1:40 1:40
38 mo 1:10 1:10 1:10
45 mo 1:10 1:40
49 mo 1:10
CDC Class. N N1 C2 C2 C1 C2 C3 C3
Antiretrovirals none none ZDV ZDV ZDV ZDV, 3TC ZDV, 3TC d4T, NVP
RNA copies/ml 750,000 750,000 487,208 155,794 32,513 247,194 673,320 ND
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lates declined in some children. For example, in child NRP
255, the titer of noncontemporaneous antibody to the virus
at 6 months in plasma from 26 and 29 months of age was
1:320, while the titer to virus isolates from 26 and 29
months of age was never higher than 1:20 in plasma ob-
tained after 29 months of age. This is also demonstrated by
NRP 274 and NRP 208. No noncontemporaneous antibody
was found to viruses isolated from NRP 208 after 44 months
of age despite follow-up of 2 and a half years and, similarly,
neutralizing antibody to isolates obtained after 36 months of
age for NRP 274 was not found. In some children, neutral-
izing antibodies to some isolates could be demonstrated for
years. Antibodies to the viruses from NRP 262 and NRP
274 at 12 months of age were present 77 months and 51
months later, respectively. Interestingly, NRP 274 contin-
ued to make neutralizing antibody for years to isolates
obtained from an earlier age (6 and 12 months) but was not
able to make antibody to isolates obtained after 36 months
of age.
Noncontemporaneous neutralizing antibodies to isolates
previously shown to be resistant to neutralization by con-
temporaneous plasma were also studied in children in the
RP group (Table 1). In 4 (RP 249, RP 202, RP 217, and RP
422), a delayed neutralizing response was also found against
neutralization resistant isolates. For the other 3 children,
follow-up was too short because of their brief survival.
Correlation of RNA levels and disease progression with
neutralizing antibodies
To determine if a correlation with disease and the pres-
ence of neutralizing antibodies could be found, the RP and
NRP were compared. This comparison was limited by the
small number of specimens available for the RP group.
Children in both groups had neutralization-resistant viruses
to antibodies in contemporaneous plasma. Both demon-
strated the generation of neutralizing antibodies to some
viruses that were previously resistant to neutralization, but
the titers in the NRP group were generally higher than those
in the RP group.
Table 1 (continued)
Virus isolate Neutralizing antibody titer with plasma obtained at age
2 wk 2 mo 6 mo 12 mo 24 mo 26 mo
RP 202
2 wk 1:10 1:40 1:80
2 mo 1:10
6 mo 1:10 1:20 1:20
12 mo 1:10
20 mo 1:10
24 mo 1:10
26 mo 1:10
CDC Class. A1 B1 B1 B2 C3 C3
Antiretrovirals none none ZDV ZDV ZDV ZDV
RNA copies/ml ND ND ND ND ND ND
a Neutralization of virus isolates with antibodies in plasma obtained at the same time (contemporaneous) and with plasma obtained later in time. Children’s
ages when virus isolates and plasma were obtained are listed in weeks and months. Neutralization titers are defined as the highest dilution of serum to inhibit
90% of virus production on day 4 after infection. CDC Class. denotes the clinical and immunological status of children at or within 3 months of the ages
listed; A  minimally symptomatic; B  moderately symptomatic; C  severely symptomatic; 1  mildly immunocompromised; 2  moderately
immunocompromised; 3  severely immunocompromised; ND  not done; NVP  nevirapine; RP  rapid progressor.
Table 2
Children with autologous contemporaneous neutralizing antibodiesa
Child Age 90%
neut
CDC
stage
Antiretrovirals RNA
copies/ml
NRP 449
2 wk 1:5 none 31,450
6 mo 1:10 B1 ZDV 750,000
12 mo 1:10 B2 ZDV 120,538
24 mo 1:80 B2 ddl 638,505
32 mo 1:40 B2 ZDV, 3TC 71,538
39 mo 1:40 B2 ZDV, 3TC 149,668
NRP 212
12 mo 1:80 A1 none 498,480
43 mo 1:40 A1 none 186,967
66 mo 1:20 A1 ZDV, ddl 79,124
NRP 236
4 mo 1:10 A1 none ND
6 mo 1:10 A1 none 750,000
12 mo 1:10 A1 none 228,185
31 mo 1:20 C1 ZDV 67,853
48 mo 1:40 C1 ddl 11,346
66 mo 1:40 C1 d4T, 3TC ND
93 mo 1:640 C1 d4T, 3TC 13,640
NRP 398
1 mo 1:10 none ND
16 mo 1:20 A2 none ND
17 mo 1:10 A2 none ND
36 mo 1:10 B2 none ND
42 mo 1:10 B3 none ND
48 mo 1:10 B2 none ND
60 mo 1:20 B3 none ND
125 mo 1:20 B3 d4T, ddl, NVP 11,518
a The neutralization titers of the 4 children with antibodies in plasma
capable of neutralizing the autologous contemporaneous isolates are listed.
Neutralization titers are defined as the highest dilution of plasma capable of
reducing viral infectivity by 90% measured on day 4 after infection.
NVP  nevirapine; ND  not done.
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Table 3
Neutralization of sequential virus isolates with antibodies in plasma collected at the same time (contemporaneous) and with plasma collected later from
nonrapid progressorsa
Virus isolate Neutralizing antibody titer with plasma obtained at age
2 wk 6 mo 26 mo 29 mo 47 mo 80 mo
NRP 255
2 wk 1:40 1:80 1:20 1:20
6 mo 1:10 1:320 1:320 1:160 1:40
26 mo 1:10 1:10 1:20 1:10
29 mo 1:10 1:10 1:10
47 mo 1:10 1:20
CDC Class. N N1 A1 A1 B2 B3
Antiretrovirals none none ddl ddl ddl d4T, ddl
RNA copies/ml ND 133,064 ND 478,953 750,000 750,000
Virus isolate Neutralizing antibody titer with plasma obtained at age
6 mo 18 mo 44 mo 53 mo 68 mo 80 mo
NRP 208
6 mo 1:20 1:80 1:160 1:160 1:10 1:10
18 mo 1:10 1:40 1:20 1:10 1:10
44 mo 1:10 1:10 1:10 1:10
53 mo 1:10 1:10 1:10
68 mo 1:10 1:10
80 mo 1:10
CDC Class. N1 B1 B1 B1 B1 B1
Antiretrovirals none none none none none ZDV, ddl
RNA copies/ml 97,129 ND 17,112 19,790 25,817 23,995
Virus isolate Neutralizing antibody titer with plasma obtained at age
3 mo 12 mo 17 mo 23 mo 43 mo 89 mo
NRP 262
3 mo 1:40 1:10 1:10 1:10 1:10 1:20
12 mo 1:10 1:160 1:320 1:640 1:320
17 mo 1:10 1:80 1:80 1:80
23 mo 1:10 1:160 1:40
43 mo 1:10
CDC Class. N1 A1 A2 A2 A1 A1
Antiretrovirals none none none none ddl ABC, d4T,
ddl
RNA copies/ml ND 650,851 551,118 116,250 ND 28,126
Virus isolate Neutralizing antibody titer with plasma obtained at age
6 mo 12 mo 36 mo 48 mo 49 mo 63 mo
NRP 274
6 mo 1:10 1:20 1:160 1:640 1:80 1:160
12 mo 1:10 1:20 1:40 1:40 1:160
36 mo 1:10 1:10 1:10
48 mo 1:10 1:10 1:10
49 mo 1:10 1:20
63 mo 1:10
CDC Class. A A2 B2 B2 B2 B2
Antiretrovirals none none ZDV, ddl ZDV, 3TC ZDV, 3TC ZDV, 3TC
RNA copies/ml 750,000 750,000 12,998 74,772 95,269 143,226
Virus isolate Neutralizing antibody titer with plasma obtained at age
6 mo 24 mo 36 mo
NRP 242
6 mo 1:10 1:320 1:160
24 mo 1:10 1:80
36 mo 1:10
CDC Class. A1 B1 B2
Antiretrovirals none ZDV ZDV
RNA copies/ml 684,034 446,448 166,406
a Neutralization of virus isolates with antibodies in plasma obtained at the same time (contemporanous) and with plasma obtained later in time. Children’s
ages when virus isolates and plasma were obtained are listed in weeks and months. Neutralization titers are defined as the highest dilution of serum to inhibit
90% of virus production on day 4 after infection.
CDC Class. denotes the clinical and immunological status of children at or within up to 3 months from the ages listed; A  minimally symptomatic; B 
moderately symptomatic; C  severely symptomatic; 1  mildly immunocompromised; 2  moderately immunocompromised; 3  severely immunocom-
promised; NRP  nonrapid progressor; ABC  abacavir; ND  not done.
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A correlation between the production of neutralizing
antibody over time and HIV RNA level was not found. This
comparison was potentially complicated by the treatment of
children with antiretroviral therapy. However, these studies
were done in children prior to the use of highly active
antiretroviral therapy (HAART) and most children were
treated with, at most, one or two drugs only.
Discussion
In this group of HIV perinatally infected children both
contemporaneous and noncontemporaneous autologous
neutralizing antibodies were present as early as the first year
of life. The occurrence of these antibodies, however, was
not consistent among children or for individual children
over time. Contemporaneous neutralizing antibodies were
found prior to 6 months of age in children with both rapid
and nonrapid disease, but the decline in titers during these
first few months suggested that the antibodies present at
birth or within a few weeks after birth were passively
acquired from their mothers. Because there were inadequate
specimens available between birth and 6 months from the
NRP group, the effect of maternal neutralizing antibodies on
disease progression in the infants could not be evaluated.
Because of the presence of maternal antibodies, the earliest
age at which contemporaneous neutralizing antibodies were
made by the infants could not be determined but noncon-
temporaneous autologous antibodies were made prior to 12
months of age by a small number of infants in both disease
groups. Although a small number of children did harbor
viruses that in vitro were neutralized by antibodies contem-
poraneous to the virus isolates, viruses isolated from the
majority of children coexisted with antibodies that could not
neutralize them in vitro. Resistant virus isolates continued
to emerge in children with both rapid and nonrapid disease.
All children with NRP and a few RP with viruses resis-
tant to contemporaneous antibodies did develop neutralizing
antibodies to earlier resistant viruses at a later time. By the
time these antibodies were detected, however, they once
again had virus that was resistant to neutralization using
contemporaneous plasma. Assessing the effect of autolo-
gous antibodies on the course of disease in these two groups
of children was not possible because of the small number of
specimens available over time from the rapid progressors. A
comparison of contemporaneous neutralizing antibody titers
and viral loads among the NRP who made autologous an-
tibodies did not reveal a clear benefit for these antibodies in
altering the quantity of plasma virus present. High viral
loads were found in children with some of the higher titers
of contemporaneous antibodies.
The results do suggest that the presence of antibodies to
previously resistant viruses is associated with suppression
of this population of viruses and the selection of a newly
resistant population. If the basis for the selection of a new
quasi-species did not involve neutralizing antibodies, new
variants would be randomly resistant or sensitive to neu-
tralization with contemporaneous plasma. Despite the in-
ferred effects on suppressing existing virus populations, the
outcome for the individual does not appear to be favorable
because the neutralizing antibodies always lag behind and
resistant virus emerges faster than the production of a new
neutralizing response. This explanation is consistent with
the high virus loads found in some children, who, despite
having a good neutralizing antibody response to earlier
viruses, lack the ability to neutralize contemporaneous ones.
The phenomenon of antigenic variation and virus escape
from neutralizing antibodies is not unique to HIV-1. It is a
known mechanism of virus survival for lentivirus infections
(Narayan et al., 1981; Montelaro et al., 1984; Salinovich et
al., 1986). In the hu-PBL-SCID mouse model, the admin-
istration of monoclonal antibodies with a high concentration
of neutralizing antibodies to HIV-1 results in the emergence
of neutralization-resistant variants within only a few days.
These data suggest that new variants can emerge quickly
(Poignard et al., 1999). In this study, it was not possible to
determine the rapidity in which neutralization-resistant vari-
ants emerged in all children because the frequency of the
sample collection was limited, but data from a few partici-
pants indicate that variants may occur as soon as 4–5
months. These results agree with those of Locher et al.
(1999), who reported the emergence of increased neutral-
ization resistance after 5 months in a vaccinee with a break-
through infection. In this study, it was only possible to
discern if sequential resistant variants were different from
each other if plasma could effectively neutralize the first
isolate but not the second. It is possible that other neutral-
ization resistant variants emerged in between and were not
identified.
An interesting characteristic of the noncontemporaneous
neutralizing antibodies was their persistent presence to vi-
ruses isolated years earlier in some children despite the
absence of neutralizing antibodies to more recent isolates.
The significance of the presence of antibodies for long
periods of time is not clear but may indicate that the virus
variants to which they are directed have not been com-
pletely eliminated. These early viruses may remain hidden
in reservoirs populated during the initial infection that con-
tinue to produce small amount of viruses that can stimulate
antibody production.
The ability of the immune system to produce antibodies
effective in neutralizing emerging variants appeared to
wane after the first few years of life in most children.
Despite the continued presence of neutralizing antibodies to
much earlier isolates and the presence of new resistant
viruses, antibodies to these new viruses were not made in
many children as they aged. Whether this was because of an
impaired immune response or because of selection of vi-
ruses that cannot be neutralized is not known. Beaumont
and collaborators (2001) found similar results in a study of
a laboratory worker accidentally infected with HIV-1 IIIB.
Sequential isolates over time from this individual were
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found to be increasingly resistant to neutralization by mono-
clonal antibodies. A study of sequential isolates for three
long-term adult nonprogressors in another study, however,
failed to find any difference in sensitivity to neutralization
using serum from an unrelated individual (Bradney et al.,
1999). The absence of a neutralizing antibody response after
some time to new isolates, together with the persistence of
antibodies to earlier isolates, may also be explained by the
phenomenon of original antigenic sin that was first de-
scribed for influenza (Fazekas de St. Groth and Webster,
1966). This doctrine suggests that there is a boost in the
antibody response to the initial virus after exposure to the
second viral variant so that subsequent strains are not rec-
ognized but the response to the original strain is continu-
ously boosted. A third possibility that could explain the
absence of response to later emerging isolates is that the
quasi-species present after a period of years is so vast, in
comparison to the earlier milieu of species, that the virus
isolated in culture does not represent the predominant spe-
cies present. This possibility is unlikely, however, because
the neutralization sensitivity of sequential isolates would be
random and would not follow a clear pattern as it does in
this study.
Finally, it has been reported that the presence of antiret-
roviral drugs in serum can result in an apparent neutraliza-
tion of HIV in in vitro tests (Dreyer et al., 1999). The
authors recommend using caution when testing plasma and
serum samples from patients treated with antiretrovirals,
especially at low dilutions. This effect is even greater when
HAART is used (Montefiori et al., 2001). In this study, the
vast majority of plasma samples were derived from children
treated with monotherapy, dual therapy, or not treated at all.
The nonspecific effect of antiretrovirals in most plasma
specimens from treated children can be ruled out because of
the absent neutralization of the contemporaneous isolate.
This occurred with multiple plasma specimens obtained
from children treated with Zidovudine (ZDV) alone or in
combination with ddI, 3TC, and with the single plasma
sample of a child treated with d4T and Nevirapine (NVP).
Inspection of neutralization reactivity in individual children
with contemporaneous neutralization again suggests little
nonspecific contribution of antiretrovirals to the reactivity
observed in children NRP 212 and NRP 398. However, for
children NRP 449 and NRP 236, this effect cannot be ruled
out at low dilutions of plasma.
This study examining the ontogeny of the neutralizing
antibodies to HIV-1 in perinatally infected children does not
support a role for neutralizing antibodies in protection from
disease. Most children harbored viruses resistant to neutral-
izing antibodies and disease continued to progress. It does,
however, provide a number of insights into the characteris-
tics of the neutralizing antibody response to HIV-1 and
raises critical questions about the evolution of these anti-
bodies and their relationship to the pathogenesis of this
infection. This study also demonstrates in children the emer-
gence of new virus variants that are often resistant to neu-
tralization. Further studies are needed to answer questions
regarding the ability of the immune system over time to
respond to new HIV-1 variants and to further explore the
role of neutralizing antibodies in the emergence of resistant
virus.
Materials and methods
Study population
Sixteen perinatally infected infants were studied. The
infants were all enrolled in one of three prospective studies
of perinatal HIV infection that were conducted at a single
institution in Miami, Florida, between 1986 and 2001. The
goals and study design of one of these studies has been
previously described (Hutto et al., 1991). The study design
for the two other studies was similar in identification, en-
rollment, and follow-up of the infants. These studies were
open to mothers and infants of all ethnicities. The present
study utilized samples obtained as part of the other three
studies and continued prospective follow-up on surviving
children. All infants and their mothers were enrolled during
the mother’s pregnancy after the mother was identified as
HIV seropositive, or within the first month after delivery.
Evaluation of the study infants began at birth or within the
first few weeks after birth. Determination of an infant’s
infection status was made on the basis of virus cultures or
HIV DNA polymerase chain reaction (PCR) assays. An
infant was considered to be infected if HIV was isolated
from the peripheral blood mononuclear cells or the PCR
assays were positive from at least two different specimens.
Specimens for culture or PCR assays were obtained begin-
ning at birth or within the first month after birth in most
infants and were repeated every 2 months during the first 6
months and then every 3 months through at least 2 years of
age. Study visits for infants determined to have HIV infec-
tion were continued after 2 years and were performed at the
time of their care if the families agreed to continue partic-
ipation in the study. For infants followed after 2 years of
age, blood specimens and detailed clinical data were ob-
tained approximately every three months.
The 16 infants chosen for studies of neutralizing anti-
bodies were selected on the basis of the availability of
specimens required for the studies. All 16 study infants had
specimens available during the first year of life including a
virus isolate with adequate infectivity (see below), and
plasma that was contemporaneous with the virus isolate. In
addition, inclusion in the study required that all children had
follow-up maintained at least through the first year of life.
Of the 16 children, seven were defined as having rapid
disease progression and nine with nonrapid progression.
Rapid progressors (RP) had severe symptoms (CDC cate-
gory C) or were severely immunocompromised (CDC cat-
egory 3) by 1 year of age. All other children were defined as
nonrapid progressors (NRP).
213R. Geffin et al. / Virology 310 (2003) 207–215
Six of the rapid progressors have been described previ-
ously (McCarthy et al., 2002). Of the seven RP, three were
female, all were Black non-Hispanic and were born between
June 1990 and July 1995. The median CD4 lymphocyte
number for the group at 12 months of age was 649/mm3
(range, 19–2334/mm3). All but one of the group are de-
ceased. The median age at the time of death was 18 months
(range, 8–30 months). The one surviving RP (217) is 108
months of age.
Of the nine children who are NRP, six are males. Eight
were African American and one was white Hispanic. They
were born between September 1989 and August 1994. The
median CD4 lymphocyte number for the group at 12
months of age was 1966/mm3 (range, 881–3338/mm3). All
are living and are at least 89 months of age. Virus isolates
were obtained from peripheral blood mononuclear cells
(PBMC) and plasma specimens used for the neutralization
studies were obtained from the same blood and were ali-
quoted and stored frozen until used.
The study was reviewed and approved by the Institu-
tional Review Board at the University of Miami. Informed
consent for participation in the study was obtained from the
parents or guardian of the child.
Study design
All neutralization assays performed for this study uti-
lized autologous plasma, i.e. plasma and virus obtained
from the same individual. Two types of autologous neutral-
ization were studied. For all individuals, ACN, neutraliza-
tion of virus by antibodies present in the same blood sample,
was studied from at least two different ages. Autologous
noncontemporaneous neutralization of virus was also eval-
uated for some children. In this assay, neutralization studies
using virus isolates from blood obtained at an earlier age
than the plasma samples were used. A plasma specimen was
considered to have a positive neutralizing antibody reactiv-
ity if the neutralization titers (as described below) were 1:10
or higher.
Virus isolation and preparation of virus stocks
Patients’ PBMC was cocultured with equal amounts of
pooled PBMC from two uninfected donors according to
conventional methods for HIV isolation. Media (RPMI sup-
plemented with 20% fetal bovine serum, 10 U/ml interleu-
kin-2, and 0.05 mg/ml gentamicin) was changed twice
weekly, and once a week fresh uninfected PBMC were
added. Virus production was monitored weekly by using a
p24 antigen-capture enzyme-linked immunosorbent assay
(ELISA) (Beckman Coulter, Miami, FL). When virus su-
pernatants reached levels higher than 10–20 ng of p24/ml,
the culture media was replaced with fresh media, and virus
stocks were prepared 48 h later and frozen at 140°C until
use. Virus infectivity was measured by using the ACTG
Virology protocol (Division of AIDS, National Institutes of
Allergy and Infectious Diseases, ACTG, Virology Manual
for HIV Laboratories 1994) and expressed as 50% of tissue
culture infectious dose (TCID50). Virus stocks with infec-
tivity of approximately 5  103 or higher were used in
neutralization assays.
Neutralization assays
Briefly, 100 TCID50 of virus stocks were incubated in
96-well, flat-bottomed tissue culture plates in triplicate with
two-fold serially diluted and heat-inactivated plasma start-
ing from a concentration of 1:10 to a concentration of 1:640.
Triplicate wells containing media (RPMI supplemented
with 20% fetal bovine serum, 10 U/ml interleukin-2, and
0.05 mg/ml gentamicin) instead of plasma served as the
nonneutralized virus control. The plates are incubated at
37°C in a humidified, 5% CO2 atmosphere for 90 min, after
which 100,000 uninfected PBMC (prestimulated with phy-
tohemmaglutinin and interleukin-2) pooled in equal parts
from two donors were added. Infection was allowed to
occur for 24 h, after which the excess plasma and virus were
removed by two consecutive washes. On day 4 after infec-
tion, 0.15 ml of virus supernatant was collected and the
virus production was measured by using a p24 antigen-
capture ELISA (Beckman Coulter). Virus neutralization ti-
ter was defined as the maximal dilution of plasma required
to reduce virus production by 90% on day 4 after infection.
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